CPHI China 2026 came to a successful close at the Shanghai New International Expo Centre, and Titan Pharmaceutical emerged with strong momentum from the three-day event. As a leading manufacturer with a solid foothold in the global cephalosporin API sector, we made significant business progress throughout the exhibition.

Our sales team engaged in productive, in-depth discussions with dozens of long-standing overseas partners, covering a wide range of strategic topics—from annual supply planning and manufacturing process upgrades to global regulatory filings and long-term supply chain collaboration. These face-to-face interactions not only reinforced the trusted relationships we have built with our global partners, but also gave us valuable insights into the latest trends shaping the anti-infective API market, further cementing our role as a key player in the worldwide cephalosporin supply chain.

Beyond the fruitful discussions, it is our underlying strengths that truly drive partner confidence.

1. An Integrated Full-Industrial-Chain Approach to Global-Quality Products

Backed by decades of technical expertise in anti-infective pharmaceuticals, Titan Pharmaceutical has established a fully integrated vertical industrial chain that spans pharmaceutical intermediates, APIs, and finished formulations. By independently developing and producing key upstream intermediates, while also scaling up cephalosporin API manufacturing and downstream drug production, we ensure full traceability and rigorous process control at every stage. This end-to-end capability guarantees consistent batch-to-batch performance, effective impurity management, and reliable product quality—offering our global partners a one-stop, compliant, and cost-efficient source of pharmaceutical raw materials.

Our company operates under a comprehensive international quality management system and holds multiple highly regarded certifications, including domestic GMP, GMP approvals from Germany, Austria, and Brazil, as well as EU CEP certificates and DMF registrations. Our flagship products, Cefuroxime Axetil and Cefuroxime Sodium, are especially favored by formulation manufacturers worldwide, thanks to their superior product specifications and our dependable large-volume supply capacity.

2. Over Two Decades of Global Reach and Commitment

Titan Pharmaceutical first ventured into international markets in 2003, and over the past 20-plus years, we have remained steadfast in our global development strategy, strictly adhering to internationally recognized pharmaceutical compliance standards. Leveraging our ample production capacity, stringent quality assurance systems, and professional regulatory support services, we now export our APIs to Europe, the Americas, the Middle East, South Asia, Southeast Asia, and beyond. Our unwavering commitment to product consistency, on-time delivery, and dedicated technical service has earned us broad recognition from pharmaceutical companies across the globe, helping to build a trusted image for Chinese pharmaceuticals in the international anti-infective API market.

The business exchanges at CPHI not only deepened our ties with existing global partners but also introduced us to a wealth of high-quality new potential partners. Looking ahead, Titan Pharmaceutical will continue to capitalize on our integrated industrial chain and EU-standard quality systems to refine production processes and expand our global regulatory portfolio. We are dedicated to connecting the global pharmaceutical supply chain with reliable Chinese manufacturing excellence, fostering win-win cooperation with partners both at home and abroad, and contributing to the healthy growth of the anti-infective pharmaceutical industry worldwide.